A Statistical Study of Lung Cancer in the Annual of Pathological Autopsy Cases in Japan, from 1958 to 1997, with Reference to Time Trends of Lung Cancer in the World-Reference-Cited by-同舟云学术

A Statistical Study of Lung Cancer in the Annual of Pathological Autopsy Cases in Japan, from 1958 to 1997, with Reference to Time Trends of Lung Cancer in the World

Published:2002-01 Issue:1 Volume:93 Page:15-23
ISSN:0910-5050
Container-title:Japanese Journal of Cancer Research
language:en
Short-container-title:

Author:

Morita Toyohiko

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1349-7006.2002.tb01195.x/fullpdf

Reference38 articles.

1. United States lung carcinoma incidence trends;Travis;Cancer,1996

2. Cigarette smoking and changes in the histopathology of lung cancer;Thun;J. Natl. Cancer Inst.,1997

3. Striking changes in smoking behaviour and lung cancer incidence by histological type in South-east Netherlands, 1960-1991;Janssen-Heijnen;Em. J. Cancer,1995

4. Incidence of lung cancer in Denmark. Historical and actual status;Skuladottir;Lung Cancer,2000

5. The trends of national hygiene;Japan Health and Welfare Statistics Association;J. Health Welfare Statistics,19601999

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Carboplatin and irinotecan (CI) vs. carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trial;Lung Cancer;2023-07

2. TWF1 induces autophagy and accelerates malignant phenotype in lung adenocarcinoma via inhibiting the cAMP signaling pathway;The FASEB Journal;2023-06-26

3. Efficacy and safety of carboplatin and etoposide in older extensive‐stage small‐cell lung cancer patients with a poor performance status;Thoracic Cancer;2023-01-25

4. A Case of Rapidly Progressing Synchronous Triple Lung Cancers;JOURNAL OF THE JAPANESE ASSOCIATION OF RURAL MEDICINE;2022

5. Prophylactic granulocyte-colony stimulating factor in patients with lung neuroendocrine carcinoma receiving platinum agents plus etoposide;Cancer Treatment and Research Communications;2021